Ultralife Corporation
NASDAQ:ULBIElectrical Equipment & Parts
+$0.08 today
- Market cap
- $261.13M
- Beta
- 0.76
- P/E (TTM)
- -12.9
- EPS (TTM)
- -$0.49
Volume 0.10M
Average 0.05M
ULBI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ultralife CorporationNASDAQ: ULBI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.96M rose 45.8% year over year, ahead of the +16.3% change in trailing-twelve-month research & development. Sequentially, it rose 15.5% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Research & development amounted to 4.7% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.8% holds above the trailing-twelve-month pace of +16.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 9M USD
- Year-over-year change
- +8.9%
- 4-year CAGR
- +7.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9M | +8.9% |
| FY2024 | 2024-12-31 | 8.27M | +9.8% |
| FY2023 | 2023-12-31 | 7.53M | +6.4% |
| FY2022 | 2022-12-31 | 7.08M | +3.7% |
| FY2021 | 2021-12-31 | 6.83M | — |
Research & Development vs competitors
How ULBI compares with its peers on the latest reported figures
- ULBI's LTM Mar 2026 research & development of $9.93M is the 2nd highest of the 7 companies compared; the peer median is $68K.
- Its year-over-year change of +16.3% is the lowest of 3, against a peer median of +22126.2%.
- Research & development amounts to 5.3% of revenue for ULBI, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.63B | +27337.7% | +14.1% | 1577.8% | |
| LTM Mar 2026 | $9.93M | +16.3% | +8.3% | 5.3% | |
| LTM Mar 2026 | $754.6K | +16914.7% | — | 46.0% | |
| LTM Jan 2026 | $136K | — | — | 4.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | +30.0% | 0.0% | |
| FY2026 | $0 | — | — | — | |
| Peer median (excluding ULBI) | $68K | +22126.2% | +22.0% | 4.0% | |
Competitors are the stored peer set for ULBI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 98.27M | 131.84M | 158.64M | 164.46M | 191.16M |
| Cost of Revenue | 73.63M | 102.44M | 119.44M | 122.14M | 146.66M |
| Gross Profit | 24.64M | 29.4M | 39.2M | 42.31M | 44.5M |
| Gross Margin | 25.1% | 22.3% | 24.7% | 25.7% | 23.3% |
| Research & Development | 6.83M | 7.08M | 7.53M | 8.27M | 9M |
| Selling, General & Admin | 17.78M | 22.19M | 22.19M | 24.08M | 26.28M |
| Operating Expenses | 24.61M | 29.27M | 29.73M | 32.35M | 35.28M |
| Depreciation & Amortization | 3.54M | 4.46M | 3.91M | 4.16M | 5.5M |
| EBITDA | 3.63M | 4.96M | 15.04M | 14.4M | 1.05M |
| EBITDA Margin | 3.7% | 3.8% | 9.5% | 8.8% | 0.6% |
| Operating Income | 35K | 129K | 9.48M | 9.97M | 9.22M |
| Operating Margin | 0.0% | 0.1% | 6.0% | 6.1% | 4.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 242K | 951K | 2.02M | 1.94M | 3.95M |
| Other Income / Expenses | (186K) | (575K) | (358K) | (1.66M) | (17.62M) |
| Income Before Tax | (151K) | (446K) | 9.12M | 8.3M | (8.4M) |
| Pre-Tax Margin | -0.2% | -0.3% | 5.7% | 5.0% | -4.4% |
| Income Tax Expense | 79K | (326K) | 1.95M | 1.89M | (2.45M) |
| Net Income | (234K) | (119K) | 7.2M | 6.31M | (5.9M) |
| Net Margin | -0.2% | -0.1% | 4.5% | 3.8% | -3.1% |
| EPS (Basic) | (0.01) | (0.01) | 0.44 | 0.38 | (0.35) |
| EPS (Diluted) | (0.01) | (0.01) | 0.44 | 0.38 | (0.35) |
| Weighted Avg Shares | 16.04M | 16.13M | 16.36M | 16.56M | 16.64M |
| Weighted Avg Shares (Diluted) | 16.04M | 16.13M | 16.23M | 16.77M | 16.64M |
Ultralife Corporation
NASDAQ:ULBI
Intrinsic Alpha fair value
Locked
Current Price
$15.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.